Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
| ▸ | SORD | Q00796 | 2/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29241190 | 0.85 | GRM1 (0.47) | TRPV1SLC6A7SORD | |
| SCHEMBL23235686 | 0.85 | GRM1 (0.47) | TRPV1SLC6A7SORD | |
| SCHEMBL4815499 | 0.76 | TRPV1 (0.64) | TRPV1SORD | |
| SCHEMBL12184995 | 0.75 | KDM4E (0.50) | TRPV1EIF2AK4 | |
| SCHEMBL15022110 | 0.75 | KDM4E (0.50) | TRPV1EIF2AK4 | |
| SCHEMBL16620510 | 0.74 | CCNC (0.53) | TRPV1 | |
| SCHEMBL15022109 | 0.74 | TRPV1 (0.44) | TRPV1SORDEIF2AK4 | |
| SCHEMBL27834290 | 0.74 | CCNC (0.53) | TRPV1 | |
| SCHEMBL18228251 | 0.74 | CCNC (0.53) | TRPV1 | |
| SCHEMBL14810701 | 0.74 | LMNA (0.57) | TRPV1SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600874-B1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | DCK, DTYMK, TYMS | TRPV1 4669/4885SLC6A7 2130/4885SORD 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.